Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 17.65 percent increase over losses of $(0.34) per share from the same period last year.